Delving into the Latest Updates on ARC-100 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

NBT 287, NBT-287, TPI 287

+ [1]

Target

Tubulin

Action

inhibitors

Mechanism

Tubulin inhibitors

Therapeutic Areas

NeoplasmsNervous System DiseasesOther Diseases

Active Indication

GlioblastomaMedulloblastomaNeuroblastoma

Inactive Indication

Alzheimer DiseaseBrain InjuriesBrain metastases+ [14]

Originator Organization

Cortice Biosciences, Inc.

Active Organization

Tapestry Pharmaceuticals, Inc.

Inactive Organization

Cortice Biosciences, Inc.

The University of California, San Francisco

License Organization

CNS Pharmaceuticals, Inc.

Cortice Biosciences, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC46H63NO15

InChIKeyFDTAUJJRHBRHIJ-FDJAAIFISA-N

CAS Registry849213-15-6

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy

The purpose of this study is to determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT), corticobasal syndrome (CBS; also called corticobasal degeneration, CBD) or progressive supranuclear palsy (PSP).

Start Date01 May 2014

Sponsor / Collaborator

The University of California, San Francisco

[+2]

NCT02047214

/ TerminatedPhase 2

Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following prior radiation and temozolomide (TMZ) therapy and that has progressed following prior bevacizumab therapy.

Start Date01 Jan 2014

Sponsor / Collaborator

Cortice Biosciences, Inc.

100 Clinical Results associated with ARC-100

Login to view more data

100 Translational Medicine associated with ARC-100

Login to view more data

100 Patents (Medical) associated with ARC-100

Login to view more data

8

Literatures (Medical) associated with ARC-100

01 Jan 2024·Neuro-oncology advances

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma

Article

Author: Benkers, Tara ; Singer, Samuel ; Hsu, Sigmund ; Duic, Paul J ; Rao, Mayank ; Goldlust, Samuel A ; Nabors, Louis B ; Silberman, Sandra L ; Mohile, Nimish ; Cappello, Lori ; Farmer, George

Abstract:

Background:

Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study the safety and preliminary efficacy of TPI 287, a central nervous system penetrant microtubule stabilizer, in combination with bevacizumab (BEV) for the treatment of rGBM.

Methods:

GBM patients with up to 2 prior relapses without prior exposure to anti-angiogenic therapy were eligible. A standard 3 + 3 design was utilized to determine the maximum tolerated dose (MTD) of TPI 287. Cohorts received TPI 287 at 140–220 mg/m2 every 3 weeks and BEV 10 mg/kg every 2 weeks during 6-week cycles. An MRI was performed after each cycle, and treatment continued until progression as determined via response assessment in neuro-oncology criteria.

Results:

Twenty-four patients were enrolled at 6 centers. Treatment was generally well tolerated. Fatigue, myelosuppression, and peripheral neuropathy were the most common treatment emergent adverse events. Dose-limiting toxicity was not observed, thus the MTD was not determined. Twenty-three patients were evaluable for median and 6-month progression-free survival, which were 5.5 months (mo) and 40%, respectively. Median and 12-month overall survival were 13.4 mo and 64%, respectively. The optimal phase 2 dose was determined to be 200 mg/m2.

Conclusions:

TPI 287 can be safely combined with BEV for the treatment of rGBM and preliminary efficacy supports further investigation of this combination.

01 Feb 2020·JAMA neurologyQ1 · MEDICINE

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome

Q1 · MEDICINE

Article

Author: Geldmacher, David S. ; Koestler, Mary ; Hare, Emma ; Powers, Ryan ; Shamloo, Merhdad ; Jung, Joo In ; Rosen, Howard J. ; Tsai, Richard M. ; Chuu, Emmeline L. ; Luong, Phi N. ; Mumford, Paige ; Rabinovici, Gil D. ; Wolf, Amy ; Boxer, Adam L. ; Miller, Zachary ; Ljubenkov, Peter A. ; Miller, Bruce L. ; Natelson-Love, Marissa ; Fagan, Anne M. ; Cobigo, Yann ; Wang, Ping ; Rojas, Julio C. ; Roberson, Erik D. ; McKinley, Emily C. ; Brown, Jesse A.

Importance:

Basket-design clinical trials that allow investigation of treatment effects on different clinical syndromes that share the same molecular pathophysiology have not previously been attempted in neurodegenerative disease.

Objective:

To assess the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease (AD) or the 4-repeat tauopathies (4RT) progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

Design, Setting, and Participants:

Two parallel-design, double-blind, placebo-controlled phase 1 randomized clinical trials in AD and 4RT were conducted from December 20, 2013, through May 4, 2017, at the University of California, San Francisco, and University of Alabama at Birmingham. A total of 94 patients with clinically diagnosed AD (n = 39) and 4RT (n = 55) were screened; of these, 3 refused to participate, and 10 with AD and 11 with 4RT did not meet inclusion criteria. A total of 29 patients with AD, 14 with PSP, and 30 with β-amyloid-negative CBS (determined on positron emission tomography findings) were enrolled. Data were analyzed from December 20, 2013, through May 4, 2017, based on modified intention to treat.

Interventions:

Randomization was 8:3 drug to placebo in 3 sequential dose cohorts receiving 2.0, 6.3, or 20.0 mg/m2 of intravenous TPI-287 once every 3 weeks for 9 weeks, with an optional 6-week open-label extension.

Main Outcomes and Measures:

Primary end points were safety and tolerability (maximal tolerated dose) of TPI-287. Secondary and exploratory end points included TPI-287 levels in cerebrospinal fluid (CSF) and changes on biomarker, clinical, and neuropsychology measures.

Results:

A total of 68 participants (38 men [56%]; median age, 65 [range, 50-85] years) were included in the modified intention-to-treat analysis, of whom 26 had AD (14 women [54%]; median age, 63 [range, 50-76] years), and 42 had 4RT (16 women [38%]; median age, 69 [range, 54-83] years). Three severe anaphylactoid reactions occurred in TPI-287-treated patients with AD, whereas none were seen in patients with 4RT, leading to a maximal tolerated dose of 6.3 mg/m2 for AD and 20.0 mg/m2 for 4RT. More falls (3 in the placebo group vs 11 in the TPI-287 group) and a dose-related worsening of dementia symptoms (mean [SD] in the CDR plus NACC FTLD-SB [Clinical Dementia Rating scale sum of boxes with frontotemporal dementia measures], 0.5 [1.8] in the placebo group vs 0.7 [1.6] in the TPI-287 group; median difference, 1.5 [95% CI, 0-2.5]; P = .03) were seen in patients with 4RT. Despite undetectable TPI-287 levels in CSF, CSF biomarkers demonstrated decreased chitinase-3-like protein-1 (YKL-40) levels in the 4RT treatment arm (mean [SD], -8.4 [26.0] ng/mL) compared with placebo (mean [SD], 10.4 [42.3] ng/mL; median difference, -14.6 [95% CI, -30.0 to 0.2] ng/mL; P = .048, Mann-Whitney test).

Conclusions and Relevance:

In this randomized clinical trial, TPI-287 was less tolerated in patients with AD than in those with 4RT owing to the presence of anaphylactoid reactions. The ability to reveal different tau therapeutic effects in various tauopathy syndromes suggests that basket trials are a valuable approach to tau therapeutic early clinical development.

Trial Registration:

ClinicalTrials.gov identifiers: NCT019666666 and NCT02133846.

01 May 2018·Journal of neuro-oncologyQ2 · MEDICINE

The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells

Q2 · MEDICINE

Article

Author: Urio, Sara ; Lehman, Norman L ; Mifsud, Caroline S ; McElroy, Joseph P ; Dalton, Hailey M ; Bryant, William M ; Li, Xiaohui ; King, Paul D ; Zumbar, Cory T ; Sak, Muge ; Usubalieva, Aisulu ; Farmer, George

Glioblastoma is a highly malignant disease in critical need of expanded treatment options. The AURKA inhibitor alisertib exhibits antiproliferative activity against glioblastoma in vitro and in vivo. Unlike current clinically used taxane drugs, the novel taxane TPI 287 penetrates the CNS. We tested for interactions between three selective AURKA inhibitors and TPI 287 against standard U87 and U1242 cells and primary glioblastoma neurospheres using colony formation assays. Bliss and Chou-Talalay analyses were utilized to statistically test for synergism. Morphological analysis, flow cytometry and annexin V binding were employed to examine cell cycle and apoptotic effects of these drug combinations. TPI 287 not only potentiated the cytotoxicity of the AURKA inhibitors alisertib, MLN8054 and TC-A2317, but was often potently synergistic. Morphologic and biochemical analysis of the combined effects of alisertib and TPI 287 consistently revealed synergistic induction of apoptosis. While each agent alone induces a mitotic block, slippage occurs allowing some tumor cells to avoid apoptosis. Combination treatment greatly attenuated mitotic slippage, committing the majority of cells to apoptosis. Alisertib and TPI 287 demonstrate significant synergism against glioblastoma cells largely attributable to a synergistic effect in inducing apoptosis. These results provide compelling rationale for clinical testing of alisertib and/or other AURKA inhibitors for potential combination use with TPI 287 against glioblastoma and other CNS neoplasms.

2

News (Medical) associated with ARC-100

05 Dec 2024

·www.accesswire.com

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion LeadersCompany committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cureRegister for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET.For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zurich, Switzerland; Samuel Goldlust, MD, Board-certified and fellowship-trained neuro oncologist with Saint Luke's Cancer Specialists; and Erin Dunbar, MD founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital.As part of the event, the members of the CNS Pharmaceuticals management team and participating KOLs will discuss GBM and provide an overview of Berubicin and next steps for the clinical development program. Additionally, participants will discuss the Company's second asset, TPI 287, and its development and regulatory strategy moving forward.A live video webcast of the event will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.Forward-Looking StatementsSome of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.CONTACTS:Investor Relations ContactJTC Team, LLCJenene Thomas908.824.0775[email protected]SOURCE: CNS Pharmaceuticals, Inc.

26 Dec 2007

·www.biospace.com

Tapestry Pharmaceuticals, Inc. Receives Notice Regarding Minimum Bid Price Rule

BOULDER, Colo., Dec. 21 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that it received notice on December 18, 2007 from the Nasdaq Stock Market that the minimum bid price of its common stock had fallen below $1.00 for 30 consecutive business days and that Tapestry was therefore not in compliance with Marketplace Rule 4310(c)(4). In accordance with the Nasdaq Marketplace Rule 4310(c)(8)(D), Tapestry has until June 16, 2008, which is 180 calendar days from December 18, 2007, to regain compliance. This notification does not have immediate affect on the listing of the Company's common stock. Tapestry can regain compliance with the minimum bid price rule if the bid price of its common stock closes at $1.00 or higher for a minimum of ten consecutive business days during the initial 180-day period, although Nasdaq may, in its discretion, require Tapestry to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days (but generally no more than 20 consecutive business days) before determining that Tapestry has demonstrated the ability to maintain long-term compliance. If compliance is not achieved by June 16, 2008, Tapestry will be eligible for an additional 180-day compliance period if it meets the Nasdaq Capital Market initial listing criteria as set forth in Marketplace Rule 4310(c) other than the minimum bid price requirement. If Tapestry is not eligible for an additional compliance period, or does not regain compliance during any additional compliance period, Nasdaq will provide written notice to Tapestry that its securities will be delisted. At such time, Tapestry would be able to appeal the delisting determination to a Nasdaq Listing Qualifications Panel. There can be no assurance that Tapestry will be able to regain compliance with the Nasdaq listing requirements or that its securities will not be delisted from the Nasdaq Capital Market on a basis other than failure to maintain a minimum bid price. About Tapestry Pharmaceuticals, Inc. Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. Tapestry's lead candidate, TPI 287 is in multiple Phase 2 clinical studies at this time. For more information about Tapestry and its technologies, visit Tapestry's website at glink@tapestrypharma.comlilian@sternir.comtapestry@schwartz-pr.com CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer of Tapestry Pharmaceuticals, Inc., +1-303-516-8500, glink@tapestrypharma.com; or Investor: Lilian Stern of Stern Investor Relations, Inc., +1-212-362-1200, lilian@sternir.com, for Tapestry Pharmaceuticals, Inc.; or Media: Dana Conti of Schwartz Communications, +1-781-684-0770, tapestry@schwartz-pr.com, for Tapestry Pharmaceuticals, Inc. Web site:

100 Deals associated with ARC-100

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic melanoma	Phase 2	United States	Cortice Biosciences, Inc.	01 Sep 2013
Neuroblastoma recurrent	Phase 2	United States	Cortice Biosciences, Inc.	01 Dec 2011
Medulloblastoma	Phase 2	United States	Cortice Biosciences, Inc.	01 Dec 2011
Breast Cancer	Phase 2	United States	Cortice Biosciences, Inc.	16 Aug 2011
Breast Carcinoma Metastatic in the Brain	Phase 2	United States	Cortice Biosciences, Inc.	16 Aug 2011
Glioblastoma Multiforme	Phase 2	United States	Cortice Biosciences, Inc.	01 Apr 2010
Recurrent Glioblastoma	Phase 2	United States	Cortice Biosciences, Inc.	01 Apr 2010
Pancreatic carcinoma non-resectable	Phase 2	United States	Cortice Biosciences, Inc.	01 Oct 2007
Pancreatic carcinoma non-resectable	Phase 2	Spain	Cortice Biosciences, Inc.	01 Oct 2007
Metastatic Prostate Carcinoma	Phase 2	United States	Cortice Biosciences, Inc.	01 Jan 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02133846 \| NCT01966666 (Pubmed \| JAMA Neurol) Manual	Phase 1	Alzheimer Disease \| Corticobasal degeneration \| Supranuclear Palsy, Progressive	68	TPI-287	dxezflxrxn(jpajmofzjt) = eedejudbfk sevyxvwtsb (qmhvbpdmba ) View more	Positive	01 Feb 2020
NCT02133846 \| NCT01966666 (Pubmed \| JAMA Neurol) Manual	Phase 1		68	Placebo	dxezflxrxn(jpajmofzjt) = slbdisisby sevyxvwtsb (qmhvbpdmba ) View more	Positive	01 Feb 2020
NCT01582152 (CTgov)	Phase 1/2	Recurrent Glioblastoma	12	Bevacizumab+TPI (TPI 287 160 mg/m2 + Bevacizumab)	fclpqsrnnj(rhjduwyigf) = xjdufrmtju hhmuelvufc (rjogqibyje, uwpoiukwsk - ifazlwlrqc) View more	-	05 Jun 2019
NCT01582152 (CTgov)	Phase 1/2	Recurrent Glioblastoma	12	Bevacizumab+TPI (TPI 287 140 mg/m2 + Bevacizumab)	fclpqsrnnj(rhjduwyigf) = lctebzjkmc hhmuelvufc (rjogqibyje, xwjazmfpzl - shnlrbqmkz) View more	-	05 Jun 2019
NCT01332630 (CTgov)	Phase 2	Breast Carcinoma Metastatic in the Brain \| Breast Cancer	24	Dexamethasone+TPI 287+Ranitidine+Benadryl	etxtkbfckl = vnvhdqvitb cxfdsmpchx (yyjrakytyk, drbfuztcwl - pmovdaumyf) View more	-	10 Jul 2018
CB-017 (SNO2017)	Phase 1/2	Recurrent Glioblastoma unmethylated MGMT promoter	-	TPI 287	edvnscoykx(zabxzecmxz) = meomkgzhfb paodejohuy (ktrvoouvux ) View more	Positive	06 Nov 2017
NCT01933815 (ASCO 12017 \| ASCO 22017) Manual	Phase 1/2	Recurrent Glioblastoma	24	bevacizumab+TPI 287	jrcczknoba(wllksugccj) = kktupijagf ifuzzoonjr (wqhxeypqyy ) View more	Positive	05 Jun 2017
NCT01067066 (Pubmed \| Melanoma Res) Manual	Phase 1	Metastatic melanoma	21	temozolomide+TPI 287	axaypljjzz(szaemlhgoe) = neuropathy and six patients experienced grade III neuropathy yslnwxvnuw (pgrdbteeng ) View more	Positive	01 Dec 2016
SNO2016	Phase 1/2	Recurrent Glioblastoma	-	TPI 287	cruyxplcpr(pinezokqrh) = myelosuppression (n=3) was the only drug-related grade 3/4 adverse event xmgnemwqks (sxnyjbpsfo )	Positive	07 Nov 2016
NCT01113463 (CTgov)	Phase 2	Glioblastoma Multiforme \| Recurrent Glioblastoma	17	TPI 287	edeqzzemxk = cschdknlif uiolpymxuy (khhvyhwexj, pvvrkamylq - ezwhoffuic) View more	-	31 Oct 2016
NCT00867568 (CTgov)	Phase 1	Recurrent Medulloblastoma \| Neuroblastoma \| Medulloblastoma	18	TPI 287	vmtrweoqxo = ghicsmgfci rkdtpjhcah (cvguxningi, mwrmbwnodj - igrlgyuchb) View more	-	28 Oct 2016
NCT01505608 (CTgov)	Phase 1/2	Neuroblastoma recurrent \| Neuroblastoma	14	Temozolomide+Irinotecan (Arm A- Temozolomide and Irinotecan)	krjxydyeft = hqwlnkzxdx iqnljtarii (qvhgsnkgqs, dhqufmhprf - zsyqtiaput) View more	-	28 Oct 2016
NCT01505608 (CTgov)	Phase 1/2	Neuroblastoma recurrent \| Neuroblastoma	14	Temozolomide+TPI 287+Irinotecan (Arm B- Temozolomide/Irinotecan + TPI 287)	dovymhzdgq = ibtcctolmn lmgzguqtxl (wppwlnbhgs, kctolmefgb - nylzdqkusv)	-	28 Oct 2016